307. Canavan disease Clinical trials / Disease details

Clinical trials : 6 / Drugs : 11 - (DrugBank : 5) / Drug target genes : 2 - Drug target pathways : 2

1 trial found

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04833907 (ClinicalTrials.gov)	April 1, 2021	24/3/2021	rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease	Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of AVASPA Gene Therapy ...	Canavan Disease	Drug: rAAV-Olig001-ASPA;Drug: Levetiracetam;Drug: Prednisone	Myrtelle Inc.	NULL	Active, not recruiting	3 Months	60 Months	All	24	Phase 1/Phase 2	United States

First Previous1Next Last